Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06014086 | Intratumoral PH-762 for Cutaneous Carcinoma | PHASE1 | ACTIVE NOT_RECRUITING | 30 | — | — | Nov 7, 2023 | Mar 1, 2026 | Feb 11, 2026 | 5 | United States |
Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events.
| Arm | Type | Description |
|---|---|---|
| Sequential escalating doses of PH-762. | EXPERIMENTAL | Escalating doses of PH-762 are to be tested, with an observation period between doses. |
| Name | Type | Description |
|---|---|---|
| PH-762 | DRUG | PH-762 is a potent RNAi molecule targeting PD-1. |
Key Inclusion Criteria: * Histologically confirmed cutaneous squamous cell carcinoma (cSCC), melanoma, or Merkel cell carcinoma, meeting one of the following criteria: * cSCC, resectable local tumors: must be Stage II or lower, amenable to curative resection and in a location where acceptable su...